-
In this issue: Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
-
1998 was a landmark year for men’s sexuality. the FDA approved sildenafil (Viagra®), a medication that now has household name familiarity.
-
-
Conventional wisdom in obstetrics implies that woen with previous uterine surgery outside the lower uterine segment — whether myomectomy or classical cesarean section — incrue an unacceptable risk for uterine rupture during pregnancy.
-
Cholesterol-reducing statin agents have been associated preclinically with cancer cell growth inhibition and metastases prevention.
-
The authors performed a two-part analysis of the contraceptive choice Project, a prospective cohort study in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost.
-
There is a known association of obesity and glucose intolerance with pancreatic cancer but whether this is due to the effect of high glucose itself, insulin resistance, or pancreatic ß-cell dysfunction is unknown. In an epidemiological, nested, case-control analysis drawn from five large prospective cohorts, measures of insulin resistance were independently associated with pancreatic cancer risk, but this was not true for measures of hyperglycemia or ß-cell dysfunction alone.
-
High-risk, early breast cancer patients treated on a dose-intense chemotherapy protocol were randomized to receive thrice weekly epoetin alfa or not. As compared with controls, hemoglobin levels were maintained and fewer red cell transfusions were required. Furthermore, there did not appear to be any detriment in progression-free or overall survival. However, venous thrombotic events occurred more frequently. The use of erythropoiesis-stimulating agents in the adjuvant setting remains unsettled.
-
A new technique of evaluating liquid-based Pap smears has been developed to identify confirmed disease-specific mutations in patients with uterine and ovarian cancers. The new technique identified most uterine and some ovarian cancers and importantly, produced no false positive screens among normal, noncancer controls.
-
n a small, multicenter, randomized Phase 2 trial, the all-oral combination of cyclophosphamide and capecitabine demonstrated a trend toward an increasing response rate when compared to capecitabine alone in the treatment of locally advanced or metastatic breast cancer. The combination was well tolerated.
